A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls.

Bartlett, David B

Connelly, Margery A

AbouAssi, Hiba

Bateman, Lori A

Tune, K Noelle

Huebner, Janet L

Kraus, Virginia B

Winegar, Deborah A

Otvos, James D

Kraus, William E

Huffman, Kim M

England

2016-05-01T23:32:51Z

2016-04-12

BACKGROUND: RA and CVD both have inflammation as part of the underlying biology. Our objective was to explore the relationships of GlycA, a measure of glycosylated acute phase proteins, with inflammation and cardiometabolic risk in RA, and explore whether these relationships were similar to those for persons without RA. METHODS: Plasma GlycA was determined for 50 individuals with mild-moderate RA disease activity and 39 controls matched for age, gender, and body mass index (BMI). Regression analyses were performed to assess relationships between GlycA and important markers of traditional inflammation and cardio-metabolic health: inflammatory cytokines, disease activity, measures of adiposity and insulin resistance. RESULTS: On average, RA activity was low (DAS-28 = 3.0 ± 1.4). Traditional inflammatory markers, ESR, hsCRP, IL-1β, IL-6, IL-18 and TNF-α were greater in RA versus controls (P < 0.05 for all). GlycA concentrations were significantly elevated in RA versus controls (P = 0.036). In RA, greater GlycA associated with disease activity (DAS-28; RDAS-28 = 0.5) and inflammation (RESR = 0.7, RhsCRP = 0.7, RIL-6 = 0.3: P < 0.05 for all); in BMI-matched controls, these inflammatory associations were absent or weaker (hsCRP), but GlycA was related to IL-18 (RhsCRP = 0.3, RIL-18 = 0.4: P < 0.05). In RA, greater GlycA associated with more total abdominal adiposity and less muscle density (Rabdominal-adiposity = 0.3, Rmuscle-density = -0.3, P < 0.05 for both). In BMI-matched controls, GlycA associated with more cardio-metabolic markers: BMI, waist circumference, adiposity measures and insulin resistance (R = 0.3-0.6, P < 0.05 for all). CONCLUSIONS: GlycA provides an integrated measure of inflammation with contributions from traditional inflammatory markers and cardio-metabolic sources, dominated by inflammatory markers in persons with RA and cardio-metabolic factors in those without.

http://www.ncbi.nlm.nih.gov/pubmed/27067270

10.1186/s13075-016-0982-5

1478-6362

https://hdl.handle.net/10161/11953

eng

Springer Science and Business Media LLC

Arthritis Res Ther

10.1186/s13075-016-0982-5

Biomarker

Glycosylation

Inflammation

Metabolic syndrome

Rheumatoid arthritis

Acute-Phase Proteins

Adiposity

Adult

Aged

Arthritis, Rheumatoid

Biomarkers

Body Mass Index

Cardiovascular Diseases

Cross-Sectional Studies

Female

Glycosylation

Humans

Inflammation

Insulin Resistance

Magnetic Resonance Spectroscopy

Male

Middle Aged

Obesity

Risk Factors

A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls.

Journal article

Bartlett, David B|0000-0001-7838-898X

Kraus, Virginia B|0000-0001-8173-8258

Kraus, William E|0000-0003-1930-9684

http://www.ncbi.nlm.nih.gov/pubmed/27067270

86

Biomedical Engineering

Clinical Science Departments

Duke

Duke Cancer Institute

Duke Molecular Physiology Institute

Institutes and Centers

Medicine

Medicine, Cardiology

Medicine, Medical Oncology

Medicine, Rheumatology and Immunology

Orthopaedics

Pathology

Pratt School of Engineering

School of Medicine

School of Nursing

School of Nursing - Secondary Group

Published online

18